![Arjan Meijeringh](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Arjan Meijeringh worked as a Business Analyst at Residex BV from 2008 to 2012.
Former positions of Arjan Meijeringh
Companies | Position | End |
---|---|---|
Residex BV
![]() Residex BV Investment ManagersFinance Residex BV is a private equity and venture capital fund manager based in Apeldoorn, Netherlands. Residex traces their history to 1987 when the firm was set up as Participatiemaatschappij BV in The Hague. The current firm was formally established in 1991. Residex is a subsidiary of Achmea Holding NV which provides insurance and financial services. The ultimate parent firm is Eureko BV, which offers insurance services as well as asset management and banking services. Since 1996, Residex focuses on investments in the healthcare sector and specializes in expansion capital, MBOs, MBIs and re-structuring transactions. They manage a number of venture funds with a healthcare/life sciences focus as well as those in biotechnology and the pharmaceutical industries. | Private Equity Analyst | 2012-05-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Residex BV
![]() Residex BV Investment ManagersFinance Residex BV is a private equity and venture capital fund manager based in Apeldoorn, Netherlands. Residex traces their history to 1987 when the firm was set up as Participatiemaatschappij BV in The Hague. The current firm was formally established in 1991. Residex is a subsidiary of Achmea Holding NV which provides insurance and financial services. The ultimate parent firm is Eureko BV, which offers insurance services as well as asset management and banking services. Since 1996, Residex focuses on investments in the healthcare sector and specializes in expansion capital, MBOs, MBIs and re-structuring transactions. They manage a number of venture funds with a healthcare/life sciences focus as well as those in biotechnology and the pharmaceutical industries. | Finance |
- Stock Market
- Insiders
- Arjan Meijeringh